Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + rituximab versus bendamustine + rituximab in previously untreated mantle cell lymphoma patients ineligible for stem cell transplantation
NL-OMON54364Phase 3Recruiting
- Sponsor
- BeiGene
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mantle cell lymphoma (MCL) and non-Hodgkin lymphoma (NHL) comparing Zanubrutinib plus rituximab followed by zanubrutinib with Bendamustine plus rituximab followed by observation (2 arms). Primary endpoint: Progression-free survival by independent central review. Started Oct 2021; status: recruiting.
02
Drugs
zanubrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON54364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54364.